Morrison called at 2 PM with the Portland numbers, and the numbers rewired Kevin's understanding of the problem the way a stack trace rewired a developer's understanding of a bug. The bug was bigger than he'd thought. The bug was always bigger than he'd thought.
"The Pearl District facility is twice the size of the Sacramento sublevel," Morrison said. "Two production rooms, not one. A dedicated cold storage unit with redundant battery backup. And complete manufacturing records going back fourteen months."
"How many vials?"
"Three hundred and twelve total production across both facilities. Sacramento produced forty-eight, all LZR-7A. Portland produced two hundred and sixty-four."
Kevin wrote the number on the notepad he'd brought from Camp Roberts, the notepad that had replaced the one on Marcus's desk, the paper surface he carried because the office chair's desk was Derek's station now and the monitoring desk was Marcus's and Kevin's place in the Sunday school room was wherever the cane could reach.
"The Portland production breaks down as follows," Morrison continued. "One hundred and eighty vials of LZR-7A. Eighty-four vials of LZR-7B."
Eighty-four. Kevin's pen stopped on the paper. Eighty-four vials of the modified strain. The strain that defeated the inhibitor. The strain that converted patients in twenty-six hours instead of seventy-two. They'd recovered ten: two from Yamamoto, eight from Holloway's trunk. That left seventy-four 7B vials somewhere in the distribution network.
"Morrison, the distribution records. Where did the seventy-four go?"
"Karen Chen is working on that now. Your Karen, at the church. She's been cross-referencing the Portland facility's shipping logs with the warehouse network data from Sacramento. She'll have the full distribution map within the hour."
Kevin put the phone down and walked to Karen's station. Walked. The cane made its sound on the tile. Karen was at the children's table with her two screens, the laptop and the hymnal-mounted monitor, her fingers moving between them the way a pianist moved between keyboards.
"The Portland shipping logs," Kevin said.
"I'm in them." Karen didn't look up. Her eyes tracked the data on both screens, the left showing the Portland facility's outbound manifests and the right showing the Meridian Logistics distribution network that she'd been mapping since the first warehouse was discovered. "The 7B vials were shipped from Portland over an eight-week period. The shipments went to Meridian warehouses in eight cities."
"Which eight?"
Karen pulled up a list. Portland. Denver. Phoenix. Houston. Atlanta. Chicago. Philadelphia. Salt Lake City. Eight cities. Eight Meridian warehouse networks. Eight sets of secondary locations and tertiary operators, each one receiving a supply of the strain that the current inhibitor couldn't stop.
"Charlotte, Nashville, Minneapolis, and Tampa received only 7A," Karen said. She tapped the screen. "Those four cities are in the standard deployment track. First-generation pathogen, standard inhibitor response expected. The other eight are in the tiered track."
"Tiered."
"The shipping manifests use that term. Tiered deployment. The 7A goes first. The local response develops, including inhibitor-based containment. Then the 7B is introduced to defeat the inhibitor. Two waves. The first wave triggers the defense. The second wave breaks it."
Sacramento was the proof of concept. Kevin had watched the concept proven in real time, had built the defense that the concept was designed to break, had seen the 7B cases appear in a green zone on Marcus's dashboard and had called Tanaka and had started the process of developing a counter-defense. The tiered deployment model was a system designed to create a response and then destroy it. The response was the target. Kevin's containment operation was what Meridian had been building toward defeating.
"The seventy-four unaccounted 7B vials," Kevin said. "Distribution across the eight cities."
Karen brought up the numbers. The distribution wasn't even. Portland had received the largest share: twenty-two vials, reflecting the city's status as the production hub. Denver: twelve. Houston: ten. Atlanta: eight. Phoenix: seven. Chicago: six. Philadelphia: five. Salt Lake City: four.
Seventy-four vials across eight cities. Some of those might still be in warehouses. Some might be at secondary locations. Some might already be in the hands of operators, sitting in coolers on kitchen counters and in bedroom closets, waiting for the word. And some, as Denver's case count was about to tell them, had already been deployed.
Kevin walked back to his notepad. He wrote the numbers. He wrote the cities. He drew a line under the eight city names and wrote TANAKA underneath.
Then he called Tanaka.
---
The call was five minutes. Tanaka's voice had the measured quality of a researcher who was doing math in his head while talking on the phone, the multitasking of a man whose laboratory was running three concurrent synthesis protocols and whose brain was the scheduling system that kept them from crashing into each other.
"The 7B inhibitor compound is on track for initial production Monday," Tanaka said. "I can produce sufficient volume for Sacramento and Portland water treatment by Monday evening. Approximately two hundred liters per city at the concentration levels required for municipal water systems."
"I need it for eight cities."
Tanaka was quiet for four seconds. The quiet of a calculator running a division problem where the dividend was fixed and the divisor had just tripled.
"Eight cities would require approximately sixteen hundred liters of 7B inhibitor compound. My laboratory's maximum output at current staffing and equipment capacity is four hundred liters per production cycle. A production cycle takes forty-eight hours. To produce sixteen hundred liters, I would need four cycles, which is eight days. Your timeline calls for delivery by Monday."
"Can you scale production?"
"Not within my facility. The synthesis requires specific equipment. Centrifuges, fume hoods, biosafety cabinets. My lab has three sets of production equipment. To scale, I would need additional laboratories with equivalent capabilities." He paused. "Mr. Park, the 7B inhibitor formula is not complex. Any university biochemistry lab with standard synthesis equipment could produce it. The CDC's emergency pharmaceutical production facility in Atlanta could produce it at ten times my capacity. But sharing the formula means the compound is no longer contained within my laboratory."
No longer contained. The 7B inhibitor was the one advantage Kevin had that Meridian didn't know about. Holloway's surveillance had ended before Tanaka identified the 7B strain and began developing the counter-compound. The formula existed only in Tanaka's lab, known only to Tanaka's team and Kevin's team and Morrison's task force. If the formula went to university labs and the CDC, it went into communications channels and procurement systems and institutional databases that Meridian's intelligence network might access.
The surprise disappeared. The defense became known. And Meridian's engineers, wherever they were, would begin designing LZR-7C the moment they learned that 7B had been countered.
"If I share the formula," Kevin said, "how fast can six additional labs produce enough for the remaining cities?"
"If the CDC's Atlanta facility and five university labs begin production Saturday, they can have sufficient volume for the six additional cities by Monday or Tuesday. The compound is straightforward to synthesize. The bottleneck is equipment calibration and quality validation, not the chemistry."
Monday or Tuesday. That matched Derek's timeline. The inhibitor reaches all eight cities before the Wednesday arrests. The defense is in the water before the management layer comes down. The tiered deployment loses its second wave.
But the formula goes wide. And the next version of the weapon starts being designed the moment the current version is countered.
Kevin put the phone down. He sat in the office chair, the one that didn't fit right anymore, and looked at the notepad. Eight cities. Seventy-four vials. Sixteen hundred liters of inhibitor. One formula.
Rachel was at the table near the piano, between calls with reporters. She'd heard Kevin's side of the conversation. She walked to the Sunday school room doorway and leaned against the frame, sketchpad under one arm, pen behind her ear, the posture she held when she was waiting for Kevin to ask the question he was going to ask.
"If I share the formula, Meridian finds out about the 7B inhibitor. They start working on 7C. Whatever we build, they build the next thing that beats it."
"And if you don't share the formula?"
"Sacramento and Portland get the defense. Six other cities don't. Not in time. The 7B deployments happen in Denver and Houston and Atlanta and the inhibitor in their water doesn't stop it, and people convert because the formula that could have saved them was sitting in one lab in Sacramento because I decided keeping a secret was more important than saving them."
Rachel looked at him. "You can't choose who gets saved."
"If I keep the formula secret, we have the advantage. For this round. Six cities pay the cost."
"And if you open it?"
"Everyone gets the defense. The advantage is gone. The next round is harder."
"Kevin." Rachel's voice dropped into the register she used for things that were simple and true and that didn't need the complexity Kevin was building around them. "Open it."
Kevin looked at the notepad. At the eight city names. At the numbers. At the math that said keeping the secret meant six cities full of people drinking water that wouldn't protect them from the thing that was coming.
He picked up the phone. He called Tanaka.
"Share the formula. The CDC in Atlanta. Five university labs with synthesis capability. Morrison can identify the labs through the task force. Production starts Saturday. Delivery by Monday."
Tanaka didn't hesitate. "I'll prepare the synthesis documentation and quality validation protocols tonight. The formula and the procedures will be ready for distribution by Friday morning."
Kevin hung up. He wrote FORMULA: OPEN on the notepad. He looked at Rachel. She was still in the doorway.
"Thank you," he said.
"For what?"
"For making simple things sound simple."
"They are simple. You make them complicated because you're a programmer and programmers think everything is an architecture problem." She pushed off the doorframe. "This wasn't an architecture problem. It was a math problem. The math says more people alive is better than fewer people alive. You didn't need me to tell you that."
"I needed you to say it out loud."
Rachel went back to the piano table. She sat down and picked up her phone for the next reporter call. Kevin watched her go. She was right. The decision was simple. The consequences were complicated. But the decision was the thing that happened first, and the consequences were the thing that happened after, and you made the decision based on who lived, not based on what the enemy learned.
Marcus's dashboard chimed. Three times in quick succession, the alert cluster that meant multiple case reports arriving simultaneously. Marcus pulled off his headphones and looked at the screen.
"Kevin." Marcus's voice had the flatness it hit when he was looking at data he didn't want to be looking at. "Denver. Three new cases. 95 zip codes with full inhibitor coverage. Patients not responding to the LZR-7A inhibitor."
Denver. The 7B wave. Kevin walked to the monitoring station and looked at the dashboard. Marcus had added a national tracking panel to his system over the past two days, the panel that pulled case data from the playbook cities as their monitoring systems came online. Denver's numbers were on the right side of the screen. Twenty-eight total cases. Twenty-five in protocol. Three flagged red.
The red meant 7B. The red meant the inhibitor in Denver's water supply was running into the same wall that Sacramento's had hit in the 95819 zip code. The tiered deployment was active. The second wave had reached Denver.
Kevin looked at the three red pins on the Denver panel. He looked at the notepad where he'd written FORMULA: OPEN. The formula was going out Friday. Production started Saturday. Delivery by Monday. Denver's 7B cases had thirty-hour conversion windows, which meant the three patients flagged today would convert by Saturday if the 7B inhibitor didn't reach Denver's water before then.
The math was tight. The math was always tight.
"Marcus, add a column to the national panel. Label it 7B STATUS. Track every non-responsive case in every playbook city. I need to see the second wave as it develops."
Marcus typed. The column appeared. Three red entries in Denver. The rest of the column was empty.
It wouldn't be empty for long.
Derek walked over from the chalkboard. He looked at the national panel. He looked at the three red pins. He looked at Kevin.
"I need to call Morrison," Derek said. "The production timeline for the six additional cities needs to account for Denver's 7B conversion rate. If the inhibitor doesn't reach Denver by Sunday, we lose the three patients."
"Sunday. Not Monday."
"Sunday." Derek was already walking to the phone. He stopped. He turned back. "Kevin. The decision to open the formula. That was the right call."
"Rachel's call."
"Rachel told you what you already knew. The call was yours." Derek went to the phone. He dialed Morrison. Kevin heard his voice in the hallway, the organizational cadence that was becoming a national coordination tool, Derek Thornton of BioVance running a twelve-city pharmaceutical distribution from a church in Midtown Sacramento because the world had run out of people who were better at logistics than a man who used to make PowerPoint slides about quarterly revenue targets.
Kevin sat in the office chair. The cane leaned against the desk. The dashboard showed Sacramento's numbers and Denver's numbers and the empty column that would fill with red as the week went on.
The formula was going out. The defense was being shared. The surprise was being spent. And somewhere, in a building or a lab or an office that Kevin hadn't found yet, someone was going to read the 7B inhibitor's molecular profile and start designing the thing that came after.
The arms race. Kevin was in an arms race with a corporation, and the corporation had forty-seven subsidiaries and a production infrastructure and engineers who built pathogens the way Kevin built software, iteratively, with each version designed to defeat the previous version's patches.
He picked up the pen. On the notepad, below the eight city names and the formula note, he wrote: *What comes after 7B?*
He didn't have an answer. The question sat on the paper and waited.
